SEVERNA PARK, Md., Dec. 3, 2012 /PRNewswire/ -- Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAY) today announced that previews of AsthmaSense™ v1.1, the latest version of its asthma management smartphone app, are available at the mHealth Summit (booth number 501-13), currently underway through December 5 at the Gaylord National™ Resort & Convention Center in National Harbor, Md. The Company expects AsthmaSense v1.1 will be available for download before the end of 2012.
AsthmaSense is the most comprehensive, yet easy-to-use smartphone app designed specifically to help improve daily monitoring and management of asthma. Users can input their medication, symptoms and peak flow results and set alerts for medication and lung function testing. In addition to using this information to alert the user to potential risk, the AsthmaSense app provides a record of the data for the patient to review with family or physician.
AsthmaSense v1.1 includes new functionality to help better manage asthma symptoms, including:
- Data synchronization and cloud storage – AsthmaSense is the first asthma app to provide safe storage of users' asthma profiles and event history/trends in a password protected, HIPAA- compliant, patient accessible cloud data warehouse.
- Trigger tracking - A profile record of personal asthma triggers to increase user awareness of potential risk patterns.
- Automatic emergency number input – Emergency contact number is automatically inputted into the phone, based on GPS location. In addition, users can edit or input their own custom emergency numbers.
- Improved help hints - Pop-up "hint bubbles" will appear on certain screens to acquaint the user with app features.
"Since we launched AsthmaSense in June 2012, the response has been overwhelmingly positive, with user feedback consistently lauding the app's features and ease-of-use. AsthmaSense v1.1 builds on that foundation with new features that allow asthmatics to feel confident that their information is always available, no matter the circumstances," said Michael Thomas, CEO of iSonea Ltd. "In the event that a user loses or breaks their smartphone, the cloud data storage feature means their data is never lost. Their entire profile and information can be retrieved, via the cloud, and uploaded to a new phone or viewed on a desktop computer. These upgrades reaffirm iSonea's commitment to keeping AsthmaSense the most intelligent, easy-to-use asthma management app on the market."
In the United States alone, 25 million people have asthma, according to the Centers for Disease Control (CDC). The CDC also estimates the cost burden in the U.S. alone exceeds $56 billion annually, as poorly controlled asthma is associated with increased emergency room visits, hospitalizations and medical costs. The World Health Organization estimates that there are more than 250,000 deaths globally from poorly controlled asthma every year. The medical community's guidelines, including those from the Global Initiative for Asthma (GINA) and the National Heart, Lung, and Blood Institute (NHLBI), state that regular monitoring of breathing symptoms is necessary to improve medication compliance and successful long-term management of asthma. It is also recommended that all people with asthma have an asthma action plan developed with their doctor to help control their asthma.
AsthmaSense is available for free at the Apple App Store (for iPhone and iPad users) and Google Play and Amazon App Stores (for Android users). Some features may not be available in all markets; contact iSonea for more information.
About iSonea Limited
iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is creating a better monitoring system—enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union. For more information, please visit www.soundasthma.com.
Forward Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
SOURCE iSonea Ltd.